Detecting Hepatitis B Surface Antigen Mutants

Coleman, Paul F.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Detecting Hepatitis B Surface Antigen Mutants

Published Date:

Feb 2006

Source:

Emerg Infect Dis. 12(2):198-203.

[PDF - 122.63 KB]

Details:

Personal Authors:

Coleman, Paul F.

Keywords:

[+]

Description:

Hepatitis B viral mutants can emerge in patients as a result of selection pressure from either immune response or treatment options. Mutations that occur within the immunodominant epitopes of hepatitis B surface antigen (HBsAg) allow mutant virus to propagate in the presence of a neutralizing immune response, while wild-type virus is reduced to undetectable levels. HBsAg mutants present as false-negative results in some immunoassays. An understanding of immunoassay reactivity with HBsAg mutants is key to establishing an appropriate testing algorithm for hepatitis B virus detection programs.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Supporting Files:

05-0038-F.gif	image/gif
05-0038-F.jpg	image/jpeg
05-0038.nxml	text/plain
license.txt	text/plain

No Related Documents.

You May Also Like:

Prevention of Perinatal Transmission of Hepatitis B Virus: Prenatal Screening of all Pregnant Women for Hepatitis B Surface Antigen

Corporate Author:

Division of Viral Hepatitis, National Center for Infectious Diseases

Source:

MMWR. Morbidity and mortality weekly report. 1988; 37(22):341-6, 351.

Description:

In 1995, highly effective inactivated hepatitis A vaccines were first licensed in the United States for preexposure prophylaxis against hepatitis A virus (HAV) among persons aged > or =2 years. In 2005, vaccine manufacturers received Food and Drug Ad...

Status:

current

File Type:

[HTML]
Nested Case-Control Study: Hepatocellular Carcinoma Risk After Hepatitis B Surface Antigen Seroclearance

Personal Author:

Gounder, Prabhu P.; Bulkow, Lisa R.; Snowball, Mary; Negus, Susan; Spradling, Philip R.; Simons, Brenna C.; McMahon, Brian J.;

Published:

Apr 08 2016

Source:

Aliment Pharmacol Ther. 43(11):1197-1207.

Description:

Background : Hepatocellular carcinoma (HCC) risk after resolving chronic hepatitis B virus (HBV) infection is unclear. : Aim : To compare HCC risk between Alaska Native (AN) patients with and without hepatitis B surface antigen (HBsAg) seroclearance....

File Type:

[PDF - 374.54 KB]
Cost-Effectiveness of Testing Hepatitis B–Positive Pregnant Women for Hepatitis B e Antigen or Viral Load

Personal Author:

Fan, Lin; Owusu-Edusei, Kwame; Schillie, Sarah F.; Murphy, Trudy V.;

Published:

May 2014

Source:

Obstet Gynecol. 123(5):929-937.

Description:

OBJECTIVE : To estimate the cost-effectiveness of testing pregnant women with hepatitis B (hepatitis B surface antigen [HBsAg]-positive) for hepatitis B e antigen (HBeAg) or hepatitis B virus (HBV) DNA, and administering maternal antiviral prophylaxi...

File Type:

[PDF - 315.22 KB]
Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors’ reply

Personal Author:

Gounder, P. P.; Bulkow, L. R.; McMahon, B. J.;

Published:

Sep 2016

Source:

Aliment Pharmacol Ther. 44(6):650-651.

Public Access
Available on:

September 01, 2017
Population-Based Longitudinal Study of Hepatitis B “e” Antigen Negative persons with Chronic Hepatitis B: Level of HBV DNA and Liver Disease

Personal Author:

McMahon, Brian J; Bulkow, Lisa; Simons, Brenna; Zhang, Yuhong; Negus, Susan; Homan, Chriss; Spradling, Philip; Teshale, Eyasu; Lau, Daryl; Snowball, Mary; Livingston, Stephen;

Published:

Sep 11 2013

Source:

Clin Gastroenterol Hepatol. 12(4):701-6.e1-3.

Description:

Conclusion : Of participants, 26% met criteria for immune active HBV. An HBV DNA level of > 20,000 IU/ml was strongly correlated with persons meeting the current guidelines for antiviral therapy.

File Type:

[PDF - 285.37 KB]